CA-NEXON-AMERICA-INC
5.6.2019 19:32:09 CEST | Business Wire | Press release
World-renowned MMORPG MapleStory announced today its highly anticipated Explorer Bowman class Pathfinder will be available to players on June 26 , with a pre-creation period starting June 12 . In the game’s update following the conclusion of the Black Mage storyline, players can explore the new Adventure Island events, take on a new theme dungeon, and level up faster with new characters via the Tera Burning Project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005050/en/
Pathfinder pre-creation will start on June 12 and will allow players to choose their Pathfinder’s features such as gender, hair color, and more before rolling out their characters for play on June 26. From June 12 to July 23, players will also enjoy the Tera Burning Project , where one new character per account will gain the extraordinary ability to gain a total of three levels each time they level up!
Starting June 12, players can also participate in a number of engaging events in Adventure Island , including Adventure Bingo, Maplerunner, Reverse Battle, and more. Through these events, players can work on their Adventurer Tier and collect Adventure Coins to purchase new items in the Adventure Coin Shop.
The update also brings massive improvements to gameplay systems to help players of all levels. These improvements include refining tutorial and job advancement quests, improving rewards for low level theme dungeons, increasing meso drops in Reboot worlds, as well as lowering quest requirements for 5th Job advancement and improving Star Force success rates and Arcane Symbol improvement costs. Multiple jobs will also be getting skill revamps in order to improve their abilities as well as increase consistency across the various jobs. The new theme dungeon, Secret Forest of Elodin, will also be available for players level 30 to 59 to explore.
Players who visit the Return to Adventure event now through June 10 can earn the Adventure Microsite Gift Box by clicking on the “Get Gifts Now” button on the page. Those who participate in the Return to Adventure event can also receive additional gift boxes with tons of new and exclusive prizes on June 12.
For more details on the MapleStory Pathfinder update, visit http://bit.ly/bw-maplestory-pathfinder .
Assets :
Social Media:
About MapleStory
With 14 years of sustained gaming excellence, MapleStory remains a critically acclaimed classic MMORPG with millions of registered active players around the world. First released in North America in 2005, MapleStory has experienced memorable in-game events, over 274 million created characters, and still is the World’s Largest Online Adventure. For more information about the game, please visit http://maplestory.nexon.net .
About Nexon America Inc. http://www.nexon.net
Nexon America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO) is a global leader in online games with more than 80 live games operated across more than 190 countries. Nexon America introduced micro-transactions and the free-to-play business model in 2005, and is widely credited with unmatched global expertise in sophisticated live game operations, nurturing player communities, and for sustaining titles for years, even decades. Nexon is listed on the Tokyo Stock Exchange, and the company was placed on the Nikkei Stock Index 300 in 2017.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605005050/en/
Contact:
Media Contact Wahid Lodin B/HI for Nexon America wahid_lodin@bhimpact.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom